Scott Bizily Sells 2,408 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

Key Points

• Scott Bizily, an insider at 4D Molecular Therapeutics, sold 2,408 shares at an average price of $10.00, reducing his position by 31.70%.
• The company's stock has shown volatility, with a one-year low of $2.23 and a high of $10.06, currently trading at approximately $9.97.
• 4D Molecular Therapeutics has seen mixed analyst ratings, with a consensus of "Moderate Buy" and an average price target of $30.40.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 2,408 shares of the business's stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $10.00, for a total transaction of $24,080.00. Following the sale, the insider directly owned 5,188 shares in the company, valued at $51,880. The trade was a 31.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Scott Bizily also recently made the following trade(s):

• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $8.00, for a total transaction of $19,256.00.

4D Molecular Therapeutics Price Performance

NASDAQ:FDMT traded up $0.30 during mid-day trading on Tuesday, hitting $9.97. 699,942 shares of the company's stock were exchanged, compared to its average volume of 843,171. 4D Molecular Therapeutics, Inc. has a one year low of $2.23 and a one year high of $10.06. The business has a fifty day moving average price of $7.23 and a 200 day moving average price of $4.97. The company has a market cap of $465.60 million, a PE ratio of -2.82 and a beta of 2.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%.The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. On average, equities analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on FDMT. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Chardan Capital reiterated a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Finally, Roth Capital reduced their price target on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $30.40.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently added to or reduced their stakes in FDMT. Russell Investments Group Ltd. grew its stake in 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company's stock worth $81,000 after acquiring an additional 2,284 shares in the last quarter. Farther Finance Advisors LLC grew its stake in 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company's stock worth $43,000 after acquiring an additional 2,674 shares in the last quarter. Dynamic Technology Lab Private Ltd grew its stake in 4D Molecular Therapeutics by 35.6% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 16,369 shares of the company's stock worth $61,000 after acquiring an additional 4,295 shares in the last quarter. American Century Companies Inc. grew its stake in 4D Molecular Therapeutics by 12.9% in the 1st quarter. American Century Companies Inc. now owns 43,784 shares of the company's stock worth $141,000 after acquiring an additional 4,999 shares in the last quarter. Finally, Proficio Capital Partners LLC grew its stake in 4D Molecular Therapeutics by 26.0% in the 1st quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company's stock worth $75,000 after acquiring an additional 5,195 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.